Modus Therapeutics publishes year-end report for 2021
STOCKHOLM, SWEDEN - 22 February 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes a year-end report for 2021. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the year-end report.John Öhd, Modus Therapeutics' CEO, commented: "This has been a transformative year for Modus, as we set out and executed on our new strategy to focus sevuparin development on sepsis, launched our oversubscribed IPO on First North, and rapidly progressed into a Phase 1b clinical trial that evaluates sevuparin during LPS